Alasdair P. Macgowan
#149,271
Most Influential Person Now
Alasdair P. Macgowan's AcademicInfluence.com Rankings
Alasdair P. Macgowanbiology Degrees
Biology
#11044
World Rank
#14419
Historical Rank
Microbiology
#617
World Rank
#685
Historical Rank
Neuroscience
#1765
World Rank
#1821
Historical Rank
Download Badge
Biology
Alasdair P. Macgowan's Degrees
- PhD Microbiology Stanford University
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Alasdair P. Macgowan Influential?
(Suggest an Edit or Addition)Alasdair P. Macgowan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The global threat of antimicrobial resistance: science for intervention (2015) (834)
- Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. (2006) (641)
- EUCAST expert rules in antimicrobial susceptibility testing. (2013) (548)
- Development of the quinolones. (2003) (443)
- A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. (2001) (391)
- European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. (2003) (361)
- European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. (2006) (355)
- The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. (2017) (346)
- Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides (2001) (332)
- Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. (2003) (272)
- Antibiotic treatment of gram-positive bone and joint infections. (2004) (268)
- Vancomycin-resistant Staphylococcus aureus (1998) (236)
- The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. (2012) (229)
- Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. (2001) (194)
- Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. (2011) (192)
- Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. (2002) (173)
- Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. (2004) (163)
- Sequence analysis of the L1 metallo-β-lactamase from Xanthomonas maltophilia (1994) (153)
- Continuous Infusion of β-Lactam Antibiotics (1998) (146)
- Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. (2000) (124)
- A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides (2006) (124)
- Genetic basis of tetracycline resistance in clinical isolates of Listeria monocytogenes (1992) (111)
- Clothing in laminar-flow operating theatres. (1996) (108)
- Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia (1997) (105)
- Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. (1998) (102)
- A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. (1992) (100)
- Surveillance of antimicrobial resistance (1998) (94)
- Clinical implications of antimicrobial resistance for therapy. (2008) (94)
- The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. (2016) (91)
- Tigecycline pharmacokinetic/pharmacodynamic update. (2008) (89)
- A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. (2001) (85)
- Distribution and expression of beta-lactamase genes among Aeromonas spp. (1997) (81)
- EUCAST technical note on tigecycline. (2006) (75)
- The passage of bacteria through surgical drapes. (2000) (75)
- The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. (2005) (75)
- Importance of air quality and related factors in the prevention of infection in orthopaedic implant surgery. (1998) (74)
- Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. (2005) (72)
- The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. (2016) (72)
- A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible beta-lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. (1995) (71)
- Nucleotide and Amino Acid Sequences of the Metallo-β-Lactamase, ImiS, from Aeromonas veronii bv. sobria (1998) (70)
- Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. (2002) (70)
- Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates (2006) (69)
- Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model (2003) (69)
- Expression of lux Genes in a Clinical Isolate of Streptococcus pneumoniae: Using Bioluminescence To Monitor Gemifloxacin Activity (2002) (68)
- European Congress of Clinical Microbiology and Infectious Disease (2004) (66)
- A prospective, randomised trial of prophylactic antibiotics versus bag extraction in the prophylaxis of wound infection in laparoscopic cholecystectomy. (2000) (64)
- Listeria monocytogenes and its role in human infection. (1988) (63)
- Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? (2011) (63)
- The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. (2001) (62)
- Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1 (2015) (60)
- The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. (1999) (59)
- The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. (2000) (58)
- Corrigendum to “The global threat of antimicrobial resistance: science for intervention” [New Microbes New Infect 6 (2015): 22–29] (2015) (58)
- Enzyme kinetics and biochemical analysis of ImiS, the metallo-beta-lactamase from Aeromonas sobria 163a. (1996) (57)
- Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. (2002) (57)
- Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. (1998) (54)
- Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. (2019) (53)
- A review of the pharmacokinetics and pharmacodynamics of aztreonam. (2016) (50)
- Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. (1997) (49)
- Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. (2016) (49)
- Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. (1999) (48)
- Pharmacodynamics of Ceftaroline against Staphylococcus aureus Studied in an In Vitro Pharmacokinetic Model of Infection (2013) (47)
- Why monitor peak vancomycin concentrations? (1995) (47)
- Sequence analysis of two chromosomally mediated inducible beta-lactamases from Aeromonas sobria, strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. (1995) (47)
- Virulence of Listeria spp.: course of infection in resistant and susceptible mice. (1988) (47)
- Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. (1999) (46)
- Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics. (2011) (45)
- Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae (2012) (44)
- Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. (2001) (44)
- Activity of Moxifloxacin, Administered Once a Day, against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model of Infection (1999) (43)
- Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized Listeria monocytogenes (1983) (43)
- Endophthalmitis at the Bristol Eye Hospital: an 11-year review of 47 patients. (1992) (42)
- An HPLC assay for daptomycin in serum. (2008) (42)
- In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models? (2001) (42)
- Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2 (2015) (42)
- Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group) (2018) (41)
- Colistin susceptibility testing: time for a review. (2014) (41)
- Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. (2010) (41)
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18. (2019) (41)
- The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. (2015) (40)
- Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. (2015) (39)
- Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. (1995) (39)
- Role of early intravenous to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two-stage replacement. (2011) (39)
- Interactions between Methicillin and Vancomycin in Methicillin-Resistant Staphylococcus aureus Strains Displaying Different Phenotypes of Vancomycin Susceptibility (1999) (38)
- Evolution of mobile genetic element composition in an epidemic methicillin-resistant Staphylococcus aureus: temporal changes correlated with frequent loss and gain events (2017) (38)
- In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. (1999) (37)
- Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. (2013) (36)
- Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. (2006) (36)
- An eight-year survey of the antimicrobial susceptibility patterns of 85,971 bacteria isolated from patients in a district general hospital and the local community. (1993) (35)
- Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever (1996) (35)
- Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study (2018) (35)
- A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone. (1996) (35)
- Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. (2006) (35)
- Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. (1990) (35)
- Antimicrobial resistance surveillance in urinary tract infections in primary care. (2016) (34)
- Prophylactic oral fluconazole and candida fungaemia (1991) (34)
- Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome (1996) (34)
- Elements of design: the knowledge on which we build. (2004) (34)
- The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. (1997) (34)
- Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. (1997) (34)
- Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study (2021) (33)
- Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin. (1999) (33)
- The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. (1995) (33)
- Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains. (2005) (32)
- Clostridium difficile-associated diarrhoea and length of hospital stay. (1995) (32)
- BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. (2002) (32)
- Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE’s STAT-Net (2018) (31)
- Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme. (2003) (31)
- The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. (2001) (31)
- The use and therapeutic drug monitoring of teicoplanin in the UK. (2004) (31)
- Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections (2018) (31)
- Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model (2008) (30)
- Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. (2012) (30)
- Listeriosis--the therapeutic options. (1990) (29)
- Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in Staphylococcus aureus (2005) (29)
- Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents (2020) (28)
- The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction (2017) (28)
- Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection (2010) (28)
- Original articles Distribution and expression of -lactamase genes among Aeromonas spp. (1997) (28)
- Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. (2003) (28)
- Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid (2003) (27)
- Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. (1994) (27)
- A comparison of the penetration of cefuroxime and cephamandole into bone, fat and haematoma fluid in patients undergoing total hip replacement. (1997) (26)
- A reverse-phase HPLC assay for the simultaneous determination of enrofloxacin and ciprofloxacin in pig faeces. (2004) (26)
- Once-daily aminoglycoside dosing (1993) (26)
- Heterogeneous resistance to vancomycin in Staphylococcus aureus. (2000) (26)
- Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia (2015) (26)
- In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). (2002) (26)
- Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study (2019) (25)
- Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection (2001) (25)
- In-vitro synergy testing of nine antimicrobial combinations against Listeria monocytogenes. (1990) (25)
- Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods. (2000) (25)
- Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. (1999) (24)
- Development of a novel assay method for colistin sulphomethate. (2005) (24)
- Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus Infection (2008) (23)
- Future treatment options for Gram-positive infections--looking ahead. (2009) (23)
- Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. (2020) (23)
- Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme. (2003) (23)
- Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. (2008) (23)
- Detection of glycopeptide resistance in Staphylococcus aureus. (2001) (23)
- A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum. (1996) (23)
- Risk factors for mortality among patients with Pseudomonas aeruginosa bacteremia - retrospective multicenter study. (2019) (23)
- Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy? (1996) (22)
- Pharmacodynamics of Razupenem (PZ601) Studied in an In Vitro Pharmacokinetic Model of Infection (2011) (22)
- Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model (2005) (22)
- Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. (2000) (22)
- Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. (1996) (22)
- Resistance determinants in strains of Clostridium difficile from two geographically distinct populations. (2004) (21)
- Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. (1998) (21)
- Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G. (1999) (21)
- Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study (2018) (21)
- Role of pharmacokinetics and pharmacodynamics: does the dose matter? (2001) (21)
- Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. (2017) (20)
- Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. (2009) (20)
- Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints (2009) (20)
- Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes. (2003) (20)
- Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis (2016) (20)
- Heterogeneity at the beta-lactamase structural gene ampC amongst Citrobacter spp. assessed by polymerase chain reaction analysis: potential for typing at a molecular level. (1994) (19)
- Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England. (2015) (19)
- Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. (2013) (19)
- Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. (1993) (18)
- Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates. (1996) (18)
- Extent, quality and impact of patient and public involvement in antimicrobial drug development research: A systematic review (2017) (18)
- Serum monitoring of teicoplanin. (1992) (18)
- Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK NEQAS for antibiotic Assays meeting for participants, October 1993. (1995) (18)
- Determination by HPLC of chlortetracycline in pig faeces. (2003) (18)
- Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an In Vitro Pharmacokinetic Model (2012) (18)
- Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net. (1997) (17)
- Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual. (2021) (17)
- Antibacterial Effects of Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae Strains for Which MICs Are High, in an In Vitro Pharmacokinetic Model (2004) (17)
- The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy. (1994) (17)
- An isocratic high performance liquid chromatography (HPLC) assay for moxifloxacin, a new 8-methoxyquinolone. (1998) (17)
- The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria. (1996) (17)
- Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. (1989) (16)
- Viral infections in pregnancy: advice for healthcare workers. (2014) (16)
- A reverse-phase, isocratic high-performance liquid chromatography assay for levofloxacin. (1999) (16)
- Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes (2017) (16)
- A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF). (2003) (15)
- The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against &bgr;-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection (2016) (15)
- Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study. (2020) (15)
- Prediction of cephalosporin and carbapenem susceptibility in multi-drug resistant Gram-negative bacteria using liquid chromatography-tandem mass spectrometry (2017) (15)
- Assay of low trough serum gentamicin concentrations by fluorescence polarization immunoassay. (1994) (15)
- Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. (2020) (15)
- Listerious—the therapeutic options (1990) (15)
- Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection (2015) (15)
- In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. (2003) (15)
- Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function. (1994) (15)
- Pharmacodynamics of antimicrobial agents and rationale for their dosing. (1997) (15)
- An audit of the use of manual handling equipment and their microbiological flora--implications for infection control. (1999) (15)
- Assay of ertapenem in human serum by high-performance liquid chromatography. (2006) (14)
- Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains. (2005) (14)
- External quality assessment of the serum bactericidal test: results of a methodology/interpretation questionnaire. (1997) (14)
- Mechanism of Fluoroquinolone Resistance Is an Important Factor in Determining the Antimicrobial Effect of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model (2003) (14)
- A new method of assessing the penetration of bacteria through fabrics used in the operating theatre. (1999) (14)
- Serum aminoglycoside concentrations: the case for routine monitoring. (1994) (14)
- The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. (1988) (14)
- Occurrence and current frequency of CTX-M-type beta-lactamases from a regional hospital in the South West of England. (2007) (14)
- HPLC assay of cefixime in serum and CSF. (1993) (13)
- A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone. (1995) (13)
- Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis. (2000) (13)
- The elution and binding characteristics of rifampicin for three commercially available protein-sealed vascular grafts. (1996) (13)
- Impact of rapid microbial identification on clinical outcomes in bloodstream infection: the RAPIDO randomised trial. (2020) (13)
- Antimicrobial therapy: principles of use (2013) (13)
- Ampicillin-aminoglycoside interaction studies using Listeria monocytogenes. (1998) (12)
- The pharmacokinetics of norfloxacin in the aged. (1988) (12)
- The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. (2001) (12)
- Pathways to optimising antibiotic use in rural China: identifying key determinants in community and clinical settings, a mixed methods study protocol (2019) (11)
- Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. (1998) (11)
- Development, validation and application of a novel HPLC‐MS/MS method for the measurement of minocycline in human plasma and urine (2019) (11)
- Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. (2021) (11)
- An in vitro biofilm model of Staphylococcus aureus infection of bone (2019) (11)
- Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility. (2010) (11)
- Epidemiology and resource utilization for patients hospitalized for lower respiratory tract infection. (2001) (11)
- In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. (2002) (11)
- Contamination of wounds by direct inoculation in total hip arthroplasty: a prospective clinical study. (1998) (11)
- Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance (2017) (11)
- Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance (2017) (11)
- The serum concentrations of desmethyl ofloxacin and ofloxacin N-oxide in seriously ill patients and their possible contributions to the antibacterial activity of ofloxacin. (1994) (10)
- Frontline antibiotic therapy. (2013) (10)
- Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING) (2016) (10)
- A comparative study of the rifampicin binding and elution characteristics for collagen- and albumin-sealed vascular grafts. (1999) (10)
- The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp. and Enterobacteriaceae resistant to second generation cephalosporins. (1995) (10)
- Pharmacokinetics of Once-a-Day Netilmicin (4.5 mg/kg) in Neonates (2001) (10)
- Characterisation of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-2018 (2019) (10)
- Nappy pad urine samples for investigation and treatment of UTI in young children: the 'DUTY' prospective diagnostic cohort study. (2016) (9)
- Ofloxacin Photodegradation Products Possess Antimicrobial Activity (1999) (9)
- Assay of serum teicoplanin concentrations in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarisation fluoroimmunoassay and bioassay. (1994) (8)
- In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. (2020) (8)
- Comparison of microbiological diagnosis of urinary tract infection in young children by routine health service laboratories and a research laboratory: Diagnostic cohort study (2017) (8)
- Challenges and opportunities for involving patients and the public in acute antimicrobial medicine development research: an interview study (2019) (8)
- Abstracts from the NIHR INVOLVE Conference 2017 (2017) (8)
- Serum monitoring and practicalities of once-daily aminoglycoside dosing. (1994) (8)
- Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection (2018) (8)
- The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. (1996) (8)
- The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing. (1993) (8)
- Modifiable healthcare factors affecting 28-day survival in bloodstream infection: a prospective cohort study (2020) (8)
- Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VISA) and heteroVISA. (2004) (7)
- Strain-Specific Expression Levels of pbp4 Exist in Isolates of Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA (2005) (7)
- MICROBIOLOGY OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS IN GREECE: A PROPOSED CLINICAL PREDICTION SCORE FOR THE CAUSATIVE PATHOGEN. (2019) (7)
- Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base? (2018) (7)
- Problems of basing patient recruitment for primary care studies on routine laboratory submissions (2007) (7)
- Continuous infusion of beta-lactam antibiotics. (1998) (7)
- Comparison of E test with conventional agar MICs for quinolones. (1994) (7)
- CLOSTRIDIA AND NEUTROPENIC ENTEROCOLITIS (1988) (7)
- In vitro studies on the impact of human serum on the antibacterial effect of faropenem. (2004) (7)
- The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. (1991) (6)
- Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region (2021) (6)
- The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model. (1999) (6)
- Challenges in the bioanalysis of tetracyclines: Epimerisation and chelation with metals. (2019) (6)
- Towards better antimicrobial susceptibility testing: impact of the Journal of Antimicrobial Chemotherapy. (2017) (6)
- Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility (2020) (6)
- Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid. (2007) (5)
- In Vitro Activities of Three New Dihydrofolate Reductase Inhibitors against Clinical Isolates of Gram-Positive Bacteria (2009) (5)
- ANAEROBIC EXPERIENCE OF FLUOROQUINOLONES AND EPIDEMIOLOGY IN THE UNITED KINGDOM AND EUROPE (1996) (5)
- In vitro Models of Infection: Pharmacokinetic/Pharmacodynamic Correlates (2000) (5)
- [Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy]. (2002) (5)
- Time-to-positivity in bloodstream infection is not a prognostic marker for mortality: analysis of a prospective multicentre randomised control trial. (2021) (5)
- Determination of avilamycin A and B in pig faeces by solid phase extraction and reverse-phase HPLC assay. (2004) (5)
- Pharmacodynamics of Ceftazidime plus the Serine β-Lactamase Inhibitor AM-112 against Escherichia coli Containing TEM-1 and CTX-M-1 β-Lactamases (2004) (5)
- Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drag FCE 22891 (1992) (5)
- Pharmacokinetics of FCE 22101 in man following different modes of administration. (1989) (5)
- A non-fatal case of hantavirus cardiopulmonary syndrome imported into the UK (ex Panama), July 2014 (2015) (5)
- Cefuroxime resistance in Haemophilus influenzae (1992) (5)
- Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases. (2004) (4)
- In Vitro Activities of Y-688, a New 7-Substituted Fluoroquinolone, against Anaerobic Bacteria (1998) (4)
- Monitoring treatment with aminoglycoside antibiotics. (1993) (4)
- Comparative evaluation of eight different in vitro pharmacodynamic models of infection. Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example. (2019) (4)
- Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2 (2020) (4)
- A long history of β-lactams for MRSA (2019) (4)
- Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection (2018) (4)
- An open study of the efficacy and safety of single dose fosfomycin trometamol in treatment of hospitalised patients with urinary tract infection (pilot study) (2005) (4)
- Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection. (2016) (4)
- Finding and engaging patients and the public to work collaboratively on an acute infection microbiology research public panel (2018) (4)
- Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures. (2019) (4)
- Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: Findings from a Mendelian randomisation study (2022) (4)
- Blood parameters measured on admission as predictors of outcome for COVID-19; a prospective UK cohort study (2020) (4)
- Use of Intravenous Co-Trimoxazole to Treat Bacterial Infection: Analysis of 50 Treatment Episodes (2010) (4)
- An evaluation of three new immunoassays for determination of serum gentamicin concentrations. (1994) (4)
- Original articles Cefuroxime resistance in non-β-lactamase Haemophilus influenzae is linked to mutations in ftsI (2003) (4)
- Once-a-day carbapenem therapy. (1996) (3)
- Trade-Offs between Antibacterial Resistance and Fitness Cost in the Production of Metallo-β-Lactamases by Enteric Bacteria Manifest as Sporadic Emergence of Carbapenem Resistance in a Clinical Setting (2021) (3)
- Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study. (2021) (3)
- 1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects (2018) (3)
- The Pharmacokinetic Profiles of Linezolid and Teicoplanin in the critically ill. (2002) (3)
- Cefuroxime axetil in the sick elderly patient. (1992) (3)
- Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship (2020) (3)
- Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study (2021) (2)
- Exploring the Pharmacokinetics of Phenoxymethylpenicillin (Penicillin-V) in Adults: A Healthy Volunteer Study (2021) (2)
- Extended Spectrum β Lactamase (ESBL) producing bacteria in a large UK NHS Hospital Trust (2007) (2)
- Treatment of Gram-positive bone and joint infection: authors' response (2004) (2)
- Difficulties in the assay of liposomal amikacin (MiKasome) in serum. (1999) (2)
- Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection. (2019) (2)
- The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. (2021) (2)
- Control of varicella-zoster infection on renal and other specialist units. (1997) (2)
- Original articles Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria (1997) (2)
- The value of MALDI-TOF failure to provide an identification of Staphylococcal species direct from blood cultures and rule out Staphylococcus aureus bacteraemia: a post-hoc analysis of the RAPIDO trial (2020) (2)
- The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection. (2020) (2)
- The activity of ceflxime against 715 urinary isolates of Enterobacteriaceae isolated from general practice and out-patients in twenty centres across tbe British Isles (1992) (2)
- Choosing the right anticoagulant: a critical choice when assessing pharmacokinetic parameters for tetracyclines obtained from human blood samples. (2019) (2)
- Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species (2022) (2)
- Determinants of urinary contamination (2016) (2)
- Brief reports Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus (1999) (2)
- Routine feedback to GPs who request microbiological tests is effective (1996) (1)
- The management of mycobacterial infection--a UK survey. (1995) (1)
- Obituary: Johan Willem Mouton. (2019) (1)
- Reply to “Breakthrough Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae during Combination Therapy with Colistin and Tigecycline” (2012) (1)
- Risk factors for hospital readmission following complicated urinary tract infection (2021) (1)
- Antimicrobial Activity of Moxifloxacin and Levofloxacin Photodegradation Products (1999) (1)
- When is penicillin monotherapy the antibiotic treatment of choice? (1992) (1)
- Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in Staphylococcus aureus (2005) (1)
- In treatment of Pseudomonas aeruginosa with piperacillin tazobactam, addition of low dose gentamicin markedly reduces emergence of resistance and increases antibacterial effect. (2014) (1)
- Comment on: The case for 'conservative pharmacotherapy'. (2021) (1)
- The Rational Choice of Antimicrobials in Life-threatening Infections on Intensive Care Units (1991) (1)
- Practical guide: Patient and public involvement in antimicrobial medicines development research (2018) (1)
- A Retrospective Evaluation of Fluoroquinolone Antibacterial Selection in a U.S. Community Hospital (2004) (1)
- Trade-Offs Between Antibacterial Resistance and Fitness Cost in the Production of Metallo-β-Lactamase by Enteric Bacteria Manifest as Sporadic Emergence of Carbapenem Resistance in a Clinical Setting (2020) (1)
- Pharmacokinetics-Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: a Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents (2020) (1)
- 1 A multi-center study evaluating the current strategies for isolating 1 Staphylococcus aureus strains with reduced susceptibility to glycopeptides 2 3 Evaluation of GISA / hGISA detection methods (2006) (1)
- Effect of Physical Activity on Age-Related Changes in Cardiac Function and Performance in Women. Circulation: Cardiovascular Imaging 2015, 8, e002086 (2016) (1)
- In Memoriam: William A. Craig (2015) (1)
- Trends in-original research published from the United Kingdom in the antimicrobial chemotherapy literature, 1980-1994. (1996) (1)
- Comment on: Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. (2020) (1)
- Vancomycin efficacy (MIC and Bactericidality) in Clinical Outcome in Patients with Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteraemia (2008) (1)
- The activity of cefixime against 715 urinary isolates of Enterobacteriaceae isolated from general practice and out-patients in twenty centres across the British Isles. (1992) (1)
- P1660 The activity of mecillinam vs Enterobacteriaceae resistant to 3rd-generation cephalosporins in Bristol, UK (2007) (1)
- Health economic analysis and modelling of diagnostic strategies (2016) (0)
- Intravenous antibiotic therapy of staphylococcal infection. (2000) (0)
- Global gene regulation and antibiotic resistance in Aeromonas spp (1999) (0)
- The pharmacodynamics of minocycline against Staphylococcus aureus in an invitro 1 pharmacokinetic model 2 3 4 5 (2008) (0)
- Daptomycin activity against Gram-Positive Cocci isolated in United Kingdom medical centers (2007) (0)
- ONTOGENY OF SUPEROXIDE ANION RELEASE BY MACROPHAGES IN NORMAL AND PLASMODIUM BERGHEI-INFECTED RATS (1981) (0)
- Derivation and validation of a clinical algorithm to guide diagnosis and treatment of urinary tract infection in pre-school children in primary care (2016) (0)
- Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models. (2022) (0)
- Case Report Forms (2016) (0)
- The pharmacokinetics of once-daily 400 mg oral ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis (1995) (0)
- Impact of Variation in the Pharmacodynamic Index Target Size on Setting Clinical Breakpoints (2008) (0)
- Trends in original research published from the United Kingdom in the antimicrobial literature. (2002) (0)
- Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07--authors' response. (2013) (0)
- Impact of recent EUCAST method changes in an English region. (2021) (0)
- The relationship between minimum inhibitory concentration and 28 day mortality in patients with a Gram-negative bloodstream infection: an analysis of data from a cohort study (BSI-FOO) (2022) (0)
- P2102 Pre-admission penicillin in patients with meningitis or meningococcal disease (2007) (0)
- Low Prevalence of Antibiotic Resistance and High Level of Antibiotic Consumption in Rural China: Interdisciplinary Study (2021) (0)
- Identification and characterisation of Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates with atypical β-lactam susceptibility profiles using Orbitrap liquid chromatography-tandem mass spectrometry (2022) (0)
- Report from the EUCAST Subcommittee on the Role of Whole Genome Sequencing ( WGS ) in Antimicrobial Susceptibility Testing of Bacteria . Version 1 , 2016 (2016) (0)
- DUTY study protocol (2016) (0)
- Developing a toolkit for patient and public involvement in antimicrobial medicines development research: Breaking new ground (2017) (0)
- 617. Pharmacodynamics of Ceftolozane-Tazobactam (C/T) as Monotherapy and in Combination with Tobramycin or Fosfomycin Against P.aeruginosa with C/T MICs at or Above 4mg/L (2022) (0)
- Down-regulaton of femB and femC genes in clinical vancomycin intermediate Staphylococcus aureus (VISA) and hetro VISA phenotypes (2003) (0)
- Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. (2022) (0)
- Pharmacokinetic Model of Infection Vitro In Staphylococcus aureus Studied in an Pharmacodynamics of Ceftaroline against (2014) (0)
- Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa. (2022) (0)
- Evolution of mobile genetic element composition in an epidemic methicillin-resistant Staphylococcus aureus: temporal changes correlated with frequent loss and gain events (2017) (0)
- Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia (2011) (0)
- Pharmacodynamics of aztreonam against Escherichia coli and Klebsiella oxytoca: defining pharmacodynamic targets. (2019) (0)
- Patient and public involvement in infection clinical research. (2018) (0)
- The measurement of blood penicillin concentration in meningococcal disease: a feasibility study (2007) (0)
- Prevalence and risk factors for acquisition of methicillin resistant staphylococcus aureus (MRSA) (2000) (0)
- Clostridium difficile after antibiotic therapy. (1994) (0)
- Antimicrobial chemotherapy (2020) (0)
- Pharmacodynamics of Ceftazidime plus the Serine (cid:2) -Lactamase Inhibitor AM-112 against Escherichia coli Containing TEM-1 and CTX-M-1 (cid:2) -Lactamases (2004) (0)
- Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891. (1992) (0)
- Clinafloxacin serum concentrations in a patient on continuous veno-venous haemofiltration. (2000) (0)
- The effect of duration of therapy for treatment of Staphylococcus aureus blood stream infection: an application of cloning to deal with immortal-time bias in an analysis of data from a cohort study (BSI-FOO) (2022) (0)
- Aeromonas hydrophila β-lactamases are part of a larger regulon, whose expression is controlled by the BlrAB two-component system (2001) (0)
- Systematic review (update) for the DUTY study: accuracy of symptoms and signs and dipstick tests for diagnosing UTI in children < 5 years old in primary care and choice of urine sampling method (2016) (0)
- Comment on: Vancomycin in adult prescribing: is it time to move on from trough-based dosing in the UK? (2022) (0)
- Pharmacokinetics of Lopinavir/Ritonavir in Hospitalized Patients with COVID-19 Not Requiring Critical Care. (2022) (0)
- Day-14 data collection forms (2016) (0)
- Overall study methods (2016) (0)
- Use of antimicrobial agents (2009) (0)
- Acute Cough in General Practice: A Prospective Observational Study of Factors Associated with Bacterial Infection and Antibiotic Receipt (2008) (0)
- Reviewers of the Journal of Chemotherapy (2010) (0)
- Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. (1989) (0)
- CHAPTER 25 – Oxazolidinones (2010) (0)
- Three-month follow-up data collection form (2016) (0)
- Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis (2016) (0)
- LISTERIOSIS (1985) (0)
- Unique Aspects of Content Unique Aspects of Software (2010) (0)
- Use of Monte Carlo Simulation (MCS) to predict MRSA Bacteraemia rates in a large English NHS Trust (2007) (0)
- Laboratory data entry forms (2016) (0)
- Comparative analysis of eleven genes from isolates of vancomycin-intermediate Staphylococcus aureus (VISA) and hVISA (2003) (0)
- S288 Optimising utility of the carbapenem class (2007) (0)
- THE PENETRATION OF LINEZOLID INTO BONE, FAT, MUSCLE AND HAEMATOMA OF PATIENTS UNDERGOING ROUTINE HIP (2003) (0)
- Current Antibiotic Treatment and Outcome for Lower Respiratory Tract Infections (1998) (0)
- Penetration of cefixime into the cerebrospinal fluid of patients with non-inflamed meninges. (1993) (0)
- Microbiological diagnosis of urinary tract infection by NHS and research laboratories (2016) (0)
- Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' response. (2019) (0)
- National Institute for Health Research Health Technology Assessment brief (2016) (0)
- Patient and public involvement toolkit for antimicrobial medicines development research (2018) (0)
- Prospective observational cohort study of patients colonised and infected with Methicillin Resistant S.aureus (MRSA) in a UK teaching hospital: Category: Clinical lesson (2011) (0)
This paper list is powered by the following services:
